Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Alzheimer's disease will be recruited for this study. The following criteria will be met for inclusion of AD subjects in this study:~  * The participant is 50 years or older.~ * Written informed consent is obtained.~ * Participants have a clinical diagnosis of Alzheimer's disease based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria.~ * Mini-Mental Status Exam score \< 25.~ * Modified Hachinski Ischemia Scale score of ≤ 4.~ * Geriatric Depression Scales (GDS) ≤ 10.~ * For females, non-child bearing potential or negative urine or blood pregnancy test on day of 123-I MNI-308 injection.~Healthy Control Subject Selection. Healthy control subjects who have no neurological disease will be recruited for this study. The following criteria will be met for inclusion of healthy control subjects in this study:~* The participant is 50 years or older.~* Written informed consent is obtained.~* Negative history of neurological or psychiatric illness based on evaluation by a research physician.~* Mini-Mental Status Exam score ≥28.~* For females, non-child bearing potential or negative urine or blood pregnancy test on day of 123-I MNI-308 injection.~Exclusion Criteria:~* Alzheimer's subjects will be excluded from participation for the following reasons:~  * The subject has signs or symptoms of another neurodegenerative disease including Parkinson's disease, diffuse Lewy body dementia, or history of significant cerebrovascular disease.~ * The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness~ * The subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery).~ * The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.~ * Pregnancy~Healthy control subjects will be excluded from participation for the following reasons:~* The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness.~* The subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery).~* The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.~* Pregnancy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy